Mark D. Wittman

Matt Grandbois

Mark Wittman received a BS (magna cum laude) in chemistry from Houghton College in 1983 and a PhD from Syracuse University in 1990 working with James Kallmerten investigating the iterative use of the Glycolate Claisen and 2,3 Wittig rearrangements to control stereochemistry in polyketide arrays. Following doctoral studies, he worked with Sam Danishefsky at Yale University investigating methods to prepare the elements of the Esperamicin/Calicheamicin trisaccharides before joining the Bristol-Myers Squibb Oncology Chemistry group in 1990. 

He is currently a Sr. Principal Scientist/Project leader at Bristol-Myers Squibb in Wallingford, CT.  In his 26 year tenure in oncology drug discovery, he has gained extensive experience in kinase drug discovery and natural product based cancer therapeutics leading to multiple compounds being advanced into the clinic. He has  20 years of experience leading multisite and multinational project teams from hit to lead through candidate nomination.

He has co-authored 37 papers, 3 reviews/book chapters, and is co-inventor on 37 issued patents and 11 patent applications.ed patents and 11 patent applications.